{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T17:17:14Z","timestamp":1694625434133},"reference-count":0,"publisher":"Hogrefe Publishing Group","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Praxis"],"published-print":{"date-parts":[[2004,3,1]]},"abstract":"<jats:p> Le but de cet article est de passer en revue le b\u00e9n\u00e9fice des diff\u00e9rents traitements de l'ost\u00e9oporose (calcium et vitamine D, raloxif\u00e8ne, bisphosphonate, calcitonine, PTH, ran\u00e9late de strontium) et de discuter pour quelle patiente avec ost\u00e9oporose ces traitements sont efficaces. L'\u00e2ge, les fractures pr\u00e9alables, et la mesure de la masse osseuse (T-score) permettent d'identifier les femmes \u00e0 haut risque pour une fracture subs\u00e9quente. Le d\u00e9veloppement de scores pour pr\u00e9dire le risque fracturaire, l'utilisation du NNT (number needed to treat), et les analyses \u00e9conomiques incluant les QALY (quality-adjusted life-year) sont d'une grande aide. Les analyses \u00e9conomiques tiennent compte des ressources n\u00e9cessaires pour obtenir ces b\u00e9n\u00e9fices. A 50 ans, seulement le calcium et la vitamine D ont un rapport co\u00fbt-efficacit\u00e9 favorable, alors qu' \u00e0 70 ans, les bisphosphonates et le raloxif\u00e8ne ont \u00e9galement un rapport co\u00fbt-efficacit\u00e9 favorable. <\/jats:p>","DOI":"10.1024\/0369-8394.93.11.399","type":"journal-article","created":{"date-parts":[[2006,1,31]],"date-time":"2006-01-31T12:10:28Z","timestamp":1138709428000},"page":"399-405","source":"Crossref","is-referenced-by-count":1,"title":["Effet des diff\u00e9rents traitements de l'ost\u00e9oporose sur la pr\u00e9vention de la fracture: vers  une approche individuelle et \u00e9conomique"],"prefix":"10.1024","volume":"93","author":[{"family":"Lamy","sequence":"first","affiliation":[{"name":"Consultation d'ost\u00e9oporose et du m\u00e9tabolisme phosphocalcique, Service de M\u00e9decine A, CHUV, Lausanne"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Krieg","sequence":"additional","affiliation":[{"name":"Consultation d'ost\u00e9oporose et du m\u00e9tabolisme phosphocalcique, Service de M\u00e9decine A, CHUV, Lausanne"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"101","container-title":["Praxis"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/econtent.hogrefe.com\/doi\/pdf\/10.1024\/0369-8394.93.11.399","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,8]],"date-time":"2022-05-08T11:15:01Z","timestamp":1652008501000},"score":1,"resource":{"primary":{"URL":"https:\/\/econtent.hogrefe.com\/doi\/10.1024\/0369-8394.93.11.399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3,1]]},"references-count":0,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2004,3,1]]}},"alternative-id":["10.1024\/0369-8394.93.11.399"],"URL":"https:\/\/doi.org\/10.1024\/0369-8394.93.11.399","relation":{},"ISSN":["1661-8157","1661-8165"],"issn-type":[{"value":"1661-8157","type":"print"},{"value":"1661-8165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,3,1]]}}}